# Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia

> **NCT00047502** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 23 (actual)

## Conditions studied

- Chronic Myelogenous Leukemia

## Interventions

- **DRUG:** Lonafarnib (SCH66336)
- **DRUG:** Imatinib Mesylate (Gleevec)

## Key facts

- **NCT ID:** NCT00047502
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11-01
- **Primary completion:** 2006-04-10
- **Final completion:** 2006-04-10
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2018-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00047502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00047502, "Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00047502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*